drugset

drugset / Trial / NCT07331792

Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor

NCT07331792 ↗

Phase 1/2 Not yet recruiting 86 enrolled Combined Military Hospital Abbottabad

RandomizedParallel-groupSingle-blindTreatment

Summary

Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial

Timeline

Start: 2026-02-02
Primary completion: 2026-05-02
Completion: 2026-05-31

Publications

Background Bamford JTM, Flores-GenuinoRNS, Ray S, Bigby M, Morales-Sánchez MA, Arkoncel M, et al. Interventions for the treatment of pityriasis versicolor. Cochrane Database Syst Rev. 2018;2018(6):CD011208. https://doi.org/10.1002/14651858.CD011208.pub2
Background Hill RC, Faria W, Gold JAW, Lipner SR. Factors associated with pityriasis versicolor in a large national database. Mycoses. 2024 Aug;67(8):e13775. doi: 10.1111/myc.13775.
Background Kurniadi I, Hendra Wijaya W, Timotius KH. Malassezia virulence factors and their role in dermatological disorders. Acta Dermatovenerol Alp Pannonica Adriat. 2022 Jun;31(2):65-70.
Background Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. Drugs Context. 2022 Nov 14;11:2022-9-2. doi: 10.7573/dic.2022-9-2. eCollection 2022.
Background Labedz N, Navarrete-Dechent C, Kubisiak-Rzepczyk H, Bowszyc-Dmochowska M, Pogorzelska-Antkowiak A, Pietkiewicz P. Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management. Life (Basel). 2023 Oct 22;13(10):2097. doi: 10.3390/life13102097.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clotrimazole	Unknown	1 %	Topical
Subject	Itraconazole	Small molecule	200 mg	Oral

Indications